Related Experiment Video
Updated: May 10, 2026
An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
Published on: March 30, 2018
Targeting Epstein-Barr virus in multiple sclerosis: when and how?
1Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
Purpose Of Review:
Epidemiological evidence implicates Epstein-Barr virus (EBV) as the cause of multiple sclerosis (MS). However, its biological role in the pathogenesis of MS is uncertain. The article provides an overview of the role of EBV in the pathogenesis of MS and makes a case for targeting EBV as a treatment strategy for MS.
Recent Findings:
EBV potentially triggers autoimmunity via molecular mimicry or immune dysregulation. Another hypothesis, supported by immunological and virological data, indicates that active EBV infection via latent-lytic infection cycling within the central nervous system or periphery drives MS disease activity. This supports testing small molecule anti-EBV agents targeting both latent and lytic infection, central nervous system-penetrant B-cell therapies and EBV-targeted immunotherapies in MS. Immunotherapies may include EBV-specific cytotoxic or chimeric antigen receptors T-cells, therapeutic EBV vaccines and immune reconstitution therapies to boost endogenous EBV-targeted cytotoxic T-cell responses.
Summary:
EBV is the probable cause of MS and is likely to be driving MS disease activity via latent-lytic infection cycling. There is evidence that all licensed MS disease-modifying therapies target EBV, and there is a compelling case for testing other anti-EBV strategies as potential treatments for MS.
Insights
Epstein-Barr virus (EBV) is strongly linked to multiple sclerosis (MS). Targeting EBV offers a promising new treatment strategy for MS patients, potentially halting disease progression.
Area of Science:
- Neuroimmunology
- Virology
- Epidemiology
Background:
- Epidemiological studies suggest Epstein-Barr virus (EBV) is a significant factor in multiple sclerosis (MS) etiology.
- The precise biological mechanisms linking EBV to MS pathogenesis remain under investigation.
Purpose of the Study:
- To review the role of EBV in MS pathogenesis.
- To present a rationale for developing EBV-targeted therapies for MS.
Main Methods:
- Review of epidemiological, immunological, and virological data.
- Analysis of existing and potential therapeutic strategies targeting EBV.
Main Results:
- EBV may trigger MS through molecular mimicry or immune dysregulation.
- Active EBV infection, cycling between latent and lytic states, is hypothesized to drive MS activity.
- Current MS therapies may indirectly target EBV, suggesting broader anti-EBV approaches are warranted.
Conclusions:
- EBV is a probable cause of MS and drives disease activity via latent-lytic cycling.
- Testing anti-EBV agents, B-cell therapies, and immunotherapies (e.g., T-cells, vaccines) is crucial for MS treatment development.
